Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lesley Fallowfield

Showing results (81-90 of 111) with videos related to

Pageof 12
Sort By:
Trials|March 2, 2021
UKCTOCS update: applying insights of delayed effects in cancer screening trials to the long-term follow-up mortality analysisMatthew Burnell, Aleksandra Gentry-Maharaj, Steven J Skates, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 4, 2017
RAZOR: A Phase II Open Randomized Trial of Screening Plus Goserelin and Raloxifene Versus Screening Alone in Premenopausal Women at Increased Risk of Breast CancerAnthony Howell, Linda Ashcroft, Lesley Fallowfield, et al.
Clinical Breast Cancer|June 3, 2025
Long-Term Safety and Efficacy of the Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection in Patients With HER2-Positive Early Breast Cancer in PHranceSCa, a Randomized, Open-Label Phase II StudyJoyce O'Shaughnessy, Susana Sousa, Josefina Cruz, et al.
Gynecologic Oncology|November 19, 2023
Ovarian cancer symptoms in pre-clinical invasive epithelial ovarian cancer - An exploratory analysis nested within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)James Dilley, Aleksandra Gentry-Maharaj, Andy Ryan, et al.
Ebiomedicine|January 14, 2025
Estimating the ovarian cancer CA-125 preclinical detectable phase, in-vivo tumour doubling time, and window for detection in early stage: an exploratory analysis of UKCTOCSJacob S Bedia, Ian J Jacobs, Andy Ryan, et al.
Breast (Edinburgh, Scotland)|March 28, 2016
Second international consensus guidelines for breast cancer in young women (BCY2)Shani Paluch-Shimon, Olivia Pagani, Ann H Partridge, et al.
Gynecologic Oncology|June 21, 2020
Ovarian cancer symptoms, routes to diagnosis and survival - Population cohort study in the 'no screen' arm of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)James Dilley, Matthew Burnell, Aleksandra Gentry-Maharaj, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 16, 2012
Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acidMiguel Martin, Richard Bell, Hugues Bourgeois, et al.
Current Oncology (Toronto, Ont.)|August 28, 2024
A Randomized Trial Comparing Concurrent versus Sequential Radiation and Endocrine Therapy in Early-Stage, Hormone-Responsive Breast CancerSharon F McGee, Mark Clemons, Gregory Pond, et al.
Trials|January 26, 2021
Completeness and accuracy of national cancer and death registration for outcome ascertainment in trials-an ovarian cancer exemplarJatinderpal K Kalsi, Andy Ryan, Aleksandra Gentry-Maharaj, et al.
Pageof 12

Showing results (81-90 of 111) with videos related to

Sort By:
Pageof 12
Trials|March 2, 2021
UKCTOCS update: applying insights of delayed effects in cancer screening trials to the long-term follow-up mortality analysisMatthew Burnell, Aleksandra Gentry-Maharaj, Steven J Skates, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 4, 2017
RAZOR: A Phase II Open Randomized Trial of Screening Plus Goserelin and Raloxifene Versus Screening Alone in Premenopausal Women at Increased Risk of Breast CancerAnthony Howell, Linda Ashcroft, Lesley Fallowfield, et al.
Clinical Breast Cancer|June 3, 2025
Long-Term Safety and Efficacy of the Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection in Patients With HER2-Positive Early Breast Cancer in PHranceSCa, a Randomized, Open-Label Phase II StudyJoyce O'Shaughnessy, Susana Sousa, Josefina Cruz, et al.
Gynecologic Oncology|November 19, 2023
Ovarian cancer symptoms in pre-clinical invasive epithelial ovarian cancer - An exploratory analysis nested within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)James Dilley, Aleksandra Gentry-Maharaj, Andy Ryan, et al.
Ebiomedicine|January 14, 2025
Estimating the ovarian cancer CA-125 preclinical detectable phase, in-vivo tumour doubling time, and window for detection in early stage: an exploratory analysis of UKCTOCSJacob S Bedia, Ian J Jacobs, Andy Ryan, et al.
Breast (Edinburgh, Scotland)|March 28, 2016
Second international consensus guidelines for breast cancer in young women (BCY2)Shani Paluch-Shimon, Olivia Pagani, Ann H Partridge, et al.
Gynecologic Oncology|June 21, 2020
Ovarian cancer symptoms, routes to diagnosis and survival - Population cohort study in the 'no screen' arm of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)James Dilley, Matthew Burnell, Aleksandra Gentry-Maharaj, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 16, 2012
Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acidMiguel Martin, Richard Bell, Hugues Bourgeois, et al.
Current Oncology (Toronto, Ont.)|August 28, 2024
A Randomized Trial Comparing Concurrent versus Sequential Radiation and Endocrine Therapy in Early-Stage, Hormone-Responsive Breast CancerSharon F McGee, Mark Clemons, Gregory Pond, et al.
Trials|January 26, 2021
Completeness and accuracy of national cancer and death registration for outcome ascertainment in trials-an ovarian cancer exemplarJatinderpal K Kalsi, Andy Ryan, Aleksandra Gentry-Maharaj, et al.
Pageof 12